Cargando…
Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative th...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873924/ https://www.ncbi.nlm.nih.gov/pubmed/35223471 http://dx.doi.org/10.3389/fonc.2022.781479 |
_version_ | 1784657569418051584 |
---|---|
author | Varadarajan, Indumathy Ballen, Karen |
author_facet | Varadarajan, Indumathy Ballen, Karen |
author_sort | Varadarajan, Indumathy |
collection | PubMed |
description | T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative therapy in eligible patients. However, allogeneic stem cell transplant is also complicated by increased rates of infections from chemotherapy, acute graft-versus-host disease (GVHD), and chronic GVHD. This review aims to report the available literature on the efficacy and complications of consolidative HSCT. It also discusses the importance of patient selection and pre- and post-transplant complications including atypical infections and GVHD. |
format | Online Article Text |
id | pubmed-8873924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88739242022-02-26 Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia Varadarajan, Indumathy Ballen, Karen Front Oncol Oncology T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative therapy in eligible patients. However, allogeneic stem cell transplant is also complicated by increased rates of infections from chemotherapy, acute graft-versus-host disease (GVHD), and chronic GVHD. This review aims to report the available literature on the efficacy and complications of consolidative HSCT. It also discusses the importance of patient selection and pre- and post-transplant complications including atypical infections and GVHD. Frontiers Media S.A. 2022-02-11 /pmc/articles/PMC8873924/ /pubmed/35223471 http://dx.doi.org/10.3389/fonc.2022.781479 Text en Copyright © 2022 Varadarajan and Ballen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Varadarajan, Indumathy Ballen, Karen Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia |
title | Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia |
title_full | Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia |
title_fullStr | Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia |
title_full_unstemmed | Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia |
title_short | Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia |
title_sort | advances in cellular therapy for t-cell prolymphocytic leukemia |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873924/ https://www.ncbi.nlm.nih.gov/pubmed/35223471 http://dx.doi.org/10.3389/fonc.2022.781479 |
work_keys_str_mv | AT varadarajanindumathy advancesincellulartherapyfortcellprolymphocyticleukemia AT ballenkaren advancesincellulartherapyfortcellprolymphocyticleukemia |